Skip to main content
SpringerLink
Log in

Correlation Between Biomarker Candidate Proteins with the Effect of Neoadjuvant Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

While chemoradiation therapy (CRT) is one of the most useful treatments for esophageal squamous cell carcinoma (ESCC), it is important to predict response prior to treatment by using markers because some patients respond well and others do not.

Methods

Fifty-nine patients with ESCC were treated with neoadjuvant CRT at the Kagoshima University Hospital. The expression of seven types of biomarker candidate proteins in biopsy specimens of untreated primary tumors was evaluated to determine whether it correlated with response and prognosis.

Results

The positive expression rates were 47% for p53, 83% for CDC25B, 68% for 14-3-3sigma, 76% for p53R2, 75% for ERCC1, 32% for Gli-1, and 54% for Nrf2. In terms of histological response, tumor grade of the 59 patients was 48.8% for grade 1 as the non-responder, 29.2% for grade 2, and 22.0% for grade 3 as the responder. CRT was significantly effective in p53(−), p53R2(−), ERCC1(−), and Nrf2(−) tumors, while p53(−), p53R2(−), and ERCC1(−) were factors independently correlated with effective histological response. Their combined expression of two or three negative expressions had 100% effective response and was a significant prognostic factor.

Conclusion

Our results suggest that two or three negative expressions of p53, p53R2, and ERCC1 in biopsy specimens of primary tumors were associated with a favorable response to CRT for ESCC. Assessment of tumor suppressor and DNA repair protein expressions in biopsy specimens may be useful for the potential utility of CRT therapy for patients with ESCC prior to treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Tachimori Y, Ozawa S, Numasaki H, et al. Comprehensive registry of esophageal cancer in Japan, 2009. Esophagus. 2016;13:110–37.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Natsugoe S, Matsumoto M, Okumura H, et al. Clinical course and outcome after esophagectomy with three-field lymphadenectomy in esophageal cancer. Langenbecks Arch Surg. 2010;395:341–46.

    Article  PubMed  Google Scholar 

  3. Tachimori Y, Ozawa S, Numasaki H, et al. Efficacy of lymph node dissection by node zones according to tumor location for esophageal squamous cell carcinoma. Esophagus. 2016;13:1–7.

    Article  PubMed  Google Scholar 

  4. Natsugoe S, Ikeda M, Baba M, et al. Long-term survivors of advanced esophageal cancer without surgical treatment: a multicenter questionnaire survey in Kyushu, Japan. Dis Esophagus. 2003;16:239–42.

    Article  CAS  PubMed  Google Scholar 

  5. Okumura H, Uchikado Y, Matsumoto M, et al. Prognostic factors in esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiation therapy. Int J Clin Oncol. 2013;8:329–34.

    Article  Google Scholar 

  6. Okumura H, Uchikado Y, Omoto I, et al. The usefulness of neoadjuvant chemoradiation therapy for locally advanced esophageal cancer with multiple lymph-node metastases. Ann Surg Oncol. 2014;21:2845–49.

    Article  PubMed  Google Scholar 

  7. Okumura H, Uchikado Y, Setoyama T, et al. Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today. 2014;44:421–28.

    Article  CAS  PubMed  Google Scholar 

  8. Sobin LH, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumours, 6th edn. New York: Wiley; 2002.

    Google Scholar 

  9. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 4th edn, part I. Esophagus. 2009;6:1–25.

  10. Japan Esophageal Society: Japanese Classification of Esophageal Cancer, 4th edn, parts II and III. Esophagus. 2009;6:71–94.

  11. Okumura H, Natsugoe S, Yokomakura N, et al. Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 2006;12:3740–45.

    Article  CAS  PubMed  Google Scholar 

  12. Miyata H, Doki Y, Shiozaki H, et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000;6:4859–65.

    CAS  PubMed  Google Scholar 

  13. Okumura H, Kita Y, Yokomakura N, et al. Nuclear expression of 14-3-3 sigma is related to prognosis in patients with esophageal squamous cell carcinoma. Anticancer Res. 2010;30:5175–79.

    PubMed  Google Scholar 

  14. Kim MK, Cho KJ, Kwon GY, et al. ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer. Eur J Cancer. 2008;44:54–60.

    Article  CAS  PubMed  Google Scholar 

  15. Yoshikawa R, Nakano Y, Tao L, et al. Hedgehog signal activation in oesophageal cancer patients undergoing neoadjuvant chemoradiotherapy. Br J Cancer. 2008;98:1670–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Kawasaki Y, Okumura H, Uchikado Y, et al. Nrf2 is useful for predicting the effect of chemoradiation therapy on esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21:2347–52.

    Article  PubMed  Google Scholar 

  17. Lowe SW, Bodis S, McClatchey A, et al. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266: 807–10.

    Article  CAS  PubMed  Google Scholar 

  18. Caelles C, Helmberg A, Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature. 1994;370:220–23.

    Article  CAS  PubMed  Google Scholar 

  19. Wagata T, Shibagaki I, Imamura M, et al. Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res. 1993;53:846–50.

    CAS  PubMed  Google Scholar 

  20. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404:42–49.

    Article  CAS  PubMed  Google Scholar 

  21. Yamaguchi T, Matsuda K, Sagiya Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res. 2001;61: 8256–62.

    CAS  PubMed  Google Scholar 

  22. Okumura H, Natsugoe S, Matsumoto M, et al. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:284–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kwon HC, Roh M, Oh SY, et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol. 2007;18:504–09.

    Article  PubMed  Google Scholar 

  24. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res. 2005;11:2215–21.

    Article  PubMed  Google Scholar 

  25. Kim MK, Cho KJ, Kwon GY, et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res. 2008;14:4225–23.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by a Grant-in-Aid for Scientists from the Ministry of Education, Culture, Sports, Science and Technology of Japan to Hiroshi Okumura (Grant Number 15K10107).

Disclosures

Masahiro Noda, Hiroshi Okumura, Yasuto Uchikado, Itaru Omoto, Ken Sasaki, Yoshiaki Kita, Shinichiro Mori, Tetsuhiro Owaki, Takaaki Arigami, Yoshikazu Uenosono, Akihiro Nakajo, Yuko Kijima, Sumiya Ishigami, Kosei Maemura, and Shoji Natsugoe have no financial disclosures to declare.

Author information

Authors and Affiliations

  1. Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, Kagoshima, Japan

    Masahiro Noda MD, Hiroshi Okumura MD, PhD, Yasuto Uchikado MD, PhD, Itaru Omoto MD, PhD, Ken Sasaki MD, PhD, Yoshiaki Kita MD, PhD, Shinichiro Mori MD, PhD, Tetsuhiro Owaki MD, PhD, Takaaki Arigami MD, PhD, Yoshikazu Uenosono MD, PhD, Akihiro Nakajo MD, PhD, Yuko Kijima MD, PhD, Sumiya Ishigami MD, PhD, Kosei Maemura MD, PhD & Shoji Natsugoe MD, PhD

Authors
  1. Masahiro Noda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroshi Okumura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuto Uchikado MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Itaru Omoto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ken Sasaki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshiaki Kita MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shinichiro Mori MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tetsuhiro Owaki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takaaki Arigami MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yoshikazu Uenosono MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Akihiro Nakajo MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Yuko Kijima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sumiya Ishigami MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Kosei Maemura MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Shoji Natsugoe MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroshi Okumura MD, PhD.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 49 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Noda, M., Okumura, H., Uchikado, Y. et al. Correlation Between Biomarker Candidate Proteins with the Effect of Neoadjuvant Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 25, 449–455 (2018). https://doi.org/10.1245/s10434-017-6271-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-6271-y

Keywords

Search

Navigation